Cargando…

Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study

Tenapanor (RDX5791/AZD1722) is a minimally systemic small‐molecule inhibitor of the sodium/hydrogen exchanger NHE3. Tenapanor acts in the gut to reduce absorption of sodium and phosphate. This phase 1 open‐label, 3‐way crossover study (NCT02226783) evaluated the effect of food on the pharmacodynamic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johansson, Susanne A., Knutsson, Mikael, Leonsson‐Zachrisson, Maria, Rosenbaum, David P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599956/ https://www.ncbi.nlm.nih.gov/pubmed/28339149 http://dx.doi.org/10.1002/cpdd.341

Ejemplares similares

A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
por: Johansson, Susanne, et al.
Publicado: (2016)

Preclinical and Healthy Volunteer Studies of Potential Drug–Drug Interactions Between Tenapanor and Phosphate Binders
por: Johansson, Susanne, et al.
Publicado: (2016)

Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions
por: Johansson, Susanne, et al.
Publicado: (2017)

Tenapanor administration and the activity of the H(+)‐coupled transporter PepT1 in healthy volunteers
por: Johansson, Susanne, et al.
Publicado: (2017)

Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers
por: Rosenbaum, David P., et al.
Publicado: (2018)

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
por: Block, Geoffrey A, et al.
Publicado: (2019)

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
por: Chey, William D, et al.
Publicado: (2017)

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)
por: Chey, William D., et al.
Publicado: (2020)

Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study
por: Silva, Arnold L., et al.
Publicado: (2023)

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
por: Chey, William D., et al.
Publicado: (2021)

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients
por: Akizawa, Tadao, et al.
Publicado: (2021)

Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial
por: Inaba, Masaaki, et al.
Publicado: (2021)

Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia
por: Nitta, Kosaku, et al.
Publicado: (2023)

Tenapanor as Add-on Treatment for Hyperphosphatemia in Dialysis Patients: Enough Bang for the Buck?
por: Wish, Jay B.
Publicado: (2023)

The NHE3 Inhibitor Tenapanor Prevents Intestinal Obstructions in CFTR-Deleted Mice
por: Tan, Xinjie, et al.
Publicado: (2022)

Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management
por: Herekar, Anam, et al.
Publicado: (2023)

Ticagrelor does not impact patient‐reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study
por: Kanter, Julie, et al.
Publicado: (2018)

Letter Regarding “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial”
por: Aoki, Yuki, et al.
Publicado: (2022)

In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”
por: Inaba, Masaaki, et al.
Publicado: (2022)

Compromised quality of life in adult patients who have received a radiation dose towards the basal part of the brain. A case-control study in long-term survivors from cancer in the head and neck region
por: Löfdahl, Elisabet, et al.
Publicado: (2012)

Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
por: Koiwa, Fumihiko, et al.
Publicado: (2023)

Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na(+)/H(+) Exchanger Isoform 3
por: Jacobs, Jeffrey W., et al.
Publicado: (2022)

Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction
por: Elborn, JS, et al.
Publicado: (2016)

Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study
por: Gao, Runlin, et al.
Publicado: (2018)

YINGLONG: A Multicenter, Prospective, Non-Interventional Study Evaluating the Safety and Tolerability of Ticagrelor in Chinese Patients with Acute Coronary Syndrome
por: Du, Xin, et al.
Publicado: (2019)

Ghrelin increases intake of rewarding food in rodents
por: Egecioglu, Emil, et al.
Publicado: (2010)

Corrigendum to Inaba M, Une Y, Ikejiri K, et al. “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial.” Kidney Int Rep. 2022;7:177–188
Publicado: (2022)

Allopregnanolone preferentially induces energy‐rich food intake in male Wistar rats
por: Holmberg, Ellinor, et al.
Publicado: (2014)

Appetite and food intake results from phase I studies of anamorelin
por: Blum, Robert A., et al.
Publicado: (2019)

Food Bioactive Compounds and Their Interference in Drug Pharmacokinetic/Pharmacodynamic Profiles
por: Briguglio, Matteo, et al.
Publicado: (2018)

Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non‐Asian participants
por: Johansson, Susanne, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P(1) Receptor Modulator in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2017)

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies
por: Brown, Karen, et al.
Publicado: (2018)

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
por: Al‐Karagholi, Mohammad Al‐Mahdi, et al.
Publicado: (2021)

Meta‐analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim
por: Gattu, Sreekanth, et al.
Publicado: (2021)

2532. Pharmacokinetic-Pharmacodynamic Analyses for Ceftobiprole Efficacy Based on Phase 3 Data from Patients with Staphylococcus aureus Bacteremia
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

The Hormonal Control of Food Intake
por: Coll, Anthony P., et al.
Publicado: (2007)

Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects
por: Wang, Shining, et al.
Publicado: (2021)

Peptides and Food Intake
por: Sobrino Crespo, Carmen, et al.
Publicado: (2014)

Nutrient scoring for the DEGS1-FFQ – from food intake to nutrient intake
por: Thieleking, Ronja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j9iel4r349oqv3nlneci5qnmhr